Entrepreneurs' Organization had seven of its members give TED-style talks on April 25. Ammar Selo

Moving the needle on something — whether it's changing the world or growing your business — hearing how others accomplished their own goals can be a beacon of hope and guidance for others.

The local Entrepreneurs' Organization chapter, EO Houston, hosted a series of seven TED Talk-style talks by members of the organization. These seven entrepreneurs discussed everything from being an introvert in a world of extroverts to the biggest security threat to American citizens: obesity. EO Talks took place at a breakfast event on April 25 at Houston Baptist University. If you missed the event, check out these overheard quotes from the day of discussions.

“When you get people involved in your organization, your job (as CEO) is alignment. Keep your team aligned with the strategic objectives of your company.”

— Paul Sarvadi, chairman, CEO and co-founder of Insperity, in his talk, "Take Care of Your People: An Entrepreneur's Journey." Connectivity is key, says Sarvadi.

“Taking care of your people is not rocket science. In fact, rocket science would be easier. It involves math and science — it works the same every day. But as soon as you put people in the mix, what worked yesterday might not work today.”

— Sarvadi continued in his talk about the importance of human resources in the the work place.

“What if everyone in the world knew what they stood for — imagine what that world would look like. We would know how we fit. We would be the best versions of ourselves. And, the world would be the best version of itself.”

— Winnie Hart, founder of TwinEngine in her talk, "What Do You Stand For?" Hart discussed finding one's identity and motivators — both in business and in life.

“Everywhere we look introverts are living in an extroverted world. It’s natural if you’re an introvert, like me, to feel a little insecure or that you feel the need to compete with your extraverted friends.”

— Darlene Gagnon, CEO and co-founder of Kinnect Global Management Services in her talk, "The Introverted Entrepreneur Competing in an Extroverted World." Gagnon says that introverts on track to be the most successful entrepreneurs with their execution skills, detail oriented nature, and ability to tune out the noise.

“It is the men in our lives that need to take action. Gentlemen, stand with us. Help us create a better presence so that we can sustain a future.”

— Shoshi Kaganovsky, CEO and founder of SensoLeak Global, in her talk, "Women Entrepreneurs—To Be..Or..To Be The Best." Kaganovsky compared how people say, "behind every great man is a woman," to how female leaders also need the support from the other gender.

“Entrepreneurship is an endless circle of reinventing yourself, being able to change, and keeping a positive attitude while doing so.”

— Kaganovsky continued in her talk as advice to the room of entrepreneurs.

“We can escape this crushing threat we call obesity. How are you going to make your escape?”

— Dr. Joe Galati, liver disease expert, radio host and author in his talk, "America's #1 National Security Threat." Galati argued that it's not Russia or North Korea that pose a major threat to the United States — it's our own health issues caused by obesity.

“We’ve all heard of the term ‘side hustle.' Maybe my dad invented the ‘side hustle.’”

— Chris Hotze, CEO and founder of Crescere Capital, in his talk, "Understanding the Power of Recurring Revenue." Hotze tells the story of how his father created a residential real estate side business out of necessity, and how that entrepreneurialism affected his own business career.

“As entrepreneurs, as long as we see control, we visualize an opportunity far greater than we see the risk.”

— Ali Nasser, CEO of AltruVista in his talk, "The Entrepreneur's Opportunity Cost," Nasser explains how entrepreneurs are hesitant to put money in the stock market, yet dive into ownership and risks for their own businesses.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”